(CRSP) Crispr Therapeutics - Ratings and Ratios
Gene-Edited Cell Therapy, CAR T Programs, In Vivo Editing, Diabetes Cell Therapy
CRSP EPS (Earnings per Share)
CRSP Revenue
Description: CRSP Crispr Therapeutics November 06, 2025
CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-based biotechnology firm that leverages its proprietary CRISPR/Cas9 platform to develop gene-edited medicines for high-unmet-need diseases. Its core technology enables precise insertion, deletion or modification of DNA sequences, positioning the company at the forefront of the rapidly expanding gene-editing sector.
The company’s lead program, **CASGEVY**, is an ex-vivo edited hematopoietic stem-cell therapy designed to reactivate fetal hemoglobin and treat transfusion-dependent β-thalassemia, sickle-cell disease and related hemoglobinopathies. In addition, CRISPR Therapeutics is advancing a diversified pipeline that includes CAR-T candidates (CTX112 for CD19-positive cancers, CTX131 for CD70-expressing tumors), in-vivo editing programs targeting ANGPTL3 and Lp(a) for cardiovascular risk reduction (CTX310/CTX320), and an allogeneic, hypo-immune stem-cell product for type-1 diabetes (CTX211).
Strategic collaborations underpin the business model: a long-term partnership with Vertex Pharmaceuticals provides a $2.5 billion upfront and milestone structure, while alliances with Nkarta and Capsida expand the company’s CAR-T and delivery capabilities. As of the latest filing, CRISPR Therapeutics reported cash and cash equivalents of roughly **$1.3 billion**, giving it an estimated runway into 2025 under current burn rates, and a market-cap of about **$5 billion**, reflecting a price-to-sales multiple near 30×-high but consistent with the biotech sector’s premium on transformative gene-editing assets. The broader gene-therapy market is projected to grow at a **CAGR of ~20 %** through 2030, driven by advancing regulatory pathways and expanding payer acceptance.
For a deeper quantitative assessment of CRISPR Therapeutics’ valuation and risk profile, see the ValueRay analysis.
CRSP Stock Overview
| Market Cap in USD | 5,131m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2016-10-19 |
CRSP Stock Ratings
| Growth Rating | 8.56% |
| Fundamental | 25.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -2.77% |
| Analyst Rating | 3.96 of 5 |
CRSP Dividends
Currently no dividends paidCRSP Growth Ratios
| Growth Correlation 3m | 66.2% |
| Growth Correlation 12m | 56.6% |
| Growth Correlation 5y | -70.1% |
| CAGR 5y | 1.17% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.02 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.04 |
| Sharpe Ratio 12m | -0.84 |
| Alpha | -17.88 |
| Beta | 1.720 |
| Volatility | 58.02% |
| Current Volume | 2745.9k |
| Average Volume 20d | 2521.7k |
| Stop Loss | 52.6 (-7.1%) |
| Signal | -1.11 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-467.8m TTM) > 0 and > 6% of Revenue (6% = 2.24m TTM) |
| FCFTA -0.16 (>2.0%) and ΔFCFTA -10.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4361 % (prev 936.5%; Δ 3425 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.16 (>3.0%) and CFO -324.8m > Net Income -467.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 16.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (87.1m) change vs 12m ago 2.53% (target <= -2.0% for YES) |
| Gross Margin -228.1% (prev 24.29%; Δ -252.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.71% (prev 8.59%; Δ -6.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.96 (EBITDA TTM -511.5m / Interest Expense TTM -66.6m) >= 6 (WARN >= 3) |
Altman Z'' -4.73
| (A) 0.80 = (Total Current Assets 1.73b - Total Current Liabilities 104.4m) / Total Assets 2.03b |
| (B) -0.84 = Retained Earnings (Balance) -1.71b / Total Assets 2.03b |
| (C) -0.24 = EBIT TTM -530.5m / Avg Total Assets 2.18b |
| (D) -5.35 = Book Value of Equity -1.70b / Total Liabilities 318.6m |
| Total Rating: -4.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.15
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -8.99% = -4.50 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda -0.04 = -2.50 |
| 6. ROIC - WACC (= -40.99)% = -12.50 |
| 7. RoE -25.25% = -2.50 |
| 8. Rev. Trend -9.82% = -0.74 |
| 9. EPS Trend 7.82% = 0.39 |
What is the price of CRSP shares?
Over the past week, the price has changed by -7.35%, over one month by -19.35%, over three months by +0.48% and over the past year by +11.61%.
Is Crispr Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRSP is around 49.47 USD . This means that CRSP is currently overvalued and has a potential downside of -12.61%.
Is CRSP a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 10
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the CRSP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 83 | 46.5% |
| Analysts Target Price | 83 | 46.5% |
| ValueRay Target Price | 57 | 0.7% |
CRSP Fundamental Data Overview November 06, 2025
P/E Forward = 23.3645
P/S = 134.8361
P/B = 3.8706
P/EG = -0.2142
Beta = 1.72
Revenue TTM = 37.4m USD
EBIT TTM = -530.5m USD
EBITDA TTM = -511.5m USD
Long Term Debt = 215.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 36.1m USD (from shortTermDebt, last quarter)
Debt = 215.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.3m USD (from netDebt column, last quarter)
Enterprise Value = 3.62b USD (5.13b + Debt 215.5m - CCE 1.72b)
Interest Coverage Ratio = -7.96 (Ebit TTM -530.5m / Interest Expense TTM -66.6m)
FCF Yield = -8.99% (FCF TTM -325.6m / Enterprise Value 3.62b)
FCF Margin = -871.5% (FCF TTM -325.6m / Revenue TTM 37.4m)
Net Margin = -1252 % (Net Income TTM -467.8m / Revenue TTM 37.4m)
Gross Margin = -228.1% ((Revenue TTM 37.4m - Cost of Revenue TTM 122.6m) / Revenue TTM)
Gross Margin QoQ = -5478 % (prev -6548 %)
Tobins Q-Ratio = 1.78 (Enterprise Value 3.62b / Total Assets 2.03b)
Interest Expense / Debt = 8.26% (Interest Expense 17.8m / Debt 215.5m)
Taxrate = -0.62% (negative due to tax credits) (1.29m / -207.3m)
NOPAT = -533.8m (EBIT -530.5m * (1 - -0.62%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 16.61 (Total Current Assets 1.73b / Total Current Liabilities 104.4m)
Debt / Equity = 0.13 (Debt 215.5m / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = -0.04 (negative EBITDA) (Net Debt 18.3m / EBITDA -511.5m)
Debt / FCF = -0.06 (negative FCF - burning cash) (Net Debt 18.3m / FCF TTM -325.6m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.05% (Net Income -467.8m / Total Assets 2.03b)
RoE = -25.25% (Net Income TTM -467.8m / Total Stockholder Equity 1.85b)
RoCE = -25.65% (EBIT -530.5m / Capital Employed (Equity 1.85b + L.T.Debt 215.5m))
RoIC = -28.81% (negative operating profit) (NOPAT -533.8m / Invested Capital 1.85b)
WACC = 12.19% (E(5.13b)/V(5.35b) * Re(12.35%) + D(215.5m)/V(5.35b) * Rd(8.26%) * (1-Tc(-0.01)))
Discount Rate = 12.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.47%
Fair Price DCF = unknown (Cash Flow -325.6m)
EPS Correlation: 7.82 | EPS CAGR: 90.33% | SUE: 2.70 | # QB: 1
Revenue Correlation: -9.82 | Revenue CAGR: 126.7% | SUE: -0.15 | # QB: 0
Additional Sources for CRSP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle